SPYRAL GEMINI Pilot Study
NCT06907147 ·
Hypertension, Vascular Diseases, Cardiovascular Diseases
RecruitingThe purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.
PhaseNA
TypeInterventional
Age18 Years – 80 Years
WhereStanford, California, United States + 17 more
SponsorMedtronic Vascular
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Pivotal Study to Evaluate the Effectiveness of Isometric Handgrip Therapy in Elevated Blood Pressure and Hypertensive Subjects
NCT06843577 · Elevated Blood Pressure,
Hypertension RecruitingThe study will be a multi-center, randomized clinical trial to evaluate the safety and efficacy of using the Zona Plus handgrip therapy device compared to the use of an auditory relaxation therapy for treatment of high blood pressure and hypertension in subjects who are not currently taking antihypertensive medications. Half of the study subjects will also be randomized to record blood pressure at home throughout the study.
PhaseNA
TypeInterventional
Age22 Years
WhereValley Village, California, United States + 9 more
SponsorZona Health, Inc
▾Tap for detailsClick for full details — eligibility, all locations, contacts Polypill for Prevention of Cardiomyopathy
RecruitingThis study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and finerenone 10 mg daily. The study duration is 6 months, and participants will be randomized to either polypill therapy or simultaneous prescription of the individual drugs. The primary outcome is change in peak VO2 and adherence to usual care. The investigators hypothesize that the use of a polypill is feasible and improves medication adherence and peak VO2 as compared to those receiving usual care.
PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 100 Years
WhereDallas, Texas, United States
SponsorUniversity of Texas Southwestern Medical Center
▾Tap for detailsClick for full details — eligibility, all locations, contacts Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404 · Coronavirus Infection (COVID-19),
Pulmonary Arterial Hypertension, Urinary Tract Infections in Children
RecruitingThe study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Phase—
TypeObservational
Age0 Years – 20 Years
WherePhoenix, Arizona, United States + 51 more
SponsorDuke University
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
RecruitingInternational, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
PhasePhase 3
TypeInterventional
Age18 Years
WhereFairhope, Alabama, United States + 770 more
SponsorAstraZeneca
▾Tap for detailsClick for full details — eligibility, all locations, contacts Harvesting Health: Advancing Nutrition and Wellness for Moms and Babies
NCT07659821 · Pregnant Women With Singleton Pregnancies
RecruitingThis is a randomized controlled trial to assess whether a personalized food kit to pregnant women is feasible, improves diet quality, and enhances pregnancy and birth outcomes compared to standard prenatal care.
PhaseNA
TypeInterventional
Age18 Years – 45 Years
WhereCollege Station, Texas, United States + 2 more
SponsorTexas A&M University
▾Tap for detailsClick for full details — eligibility, all locations, contacts HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
RecruitingStudy of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction
PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereKansas City, Missouri, United States + 2 more
Sponsor35Pharma Inc., a GSK company
▾Tap for detailsClick for full details — eligibility, all locations, contacts The PCOT study is a multi-site randomized trial of patients 70 years or older with high BP. The main goal of the study Preventing Cognitive Decline by Reducing BP Target Trial (PCOT) is to conduct a large pragmatic clinical trial (PCT) to test the hypothesis that patients who receive care with a combination of clinical decision support (CDS) and team-based care delivered in primary care practices will have better blood pressure control and a lower incidence of mild cognitive impairment and dementia than patients receiving usual medical care. Patients will be recruited from UT Southwestern Medical Center and Parkland Health \& Hospital System.
PhaseNA
TypeInterventional
Age70 Years
WhereDallas, Texas, United States
SponsorUniversity of Texas Southwestern Medical Center
▾Tap for detailsClick for full details — eligibility, all locations, contacts This Registry will look at patients being treated with a transjugular intrahepatic portosystemic shunt (TIPS) procedure for portal hypertension. The purpose of this Registry is to collect data on the safety and performance of the GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm) for 2 years in real world setting. Additionally, data will be collected on the safety and performance of the GORE TIPS Set when utilized.
Phase—
TypeObservational
Age18 Years
WhereAtlanta, Georgia, United States + 4 more
SponsorW.L.Gore & Associates
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
RecruitingA study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 100 Years
WhereScottsdale, Arizona, United States + 86 more
SponsorNovartis Pharmaceuticals
▾Tap for detailsClick for full details — eligibility, all locations, contacts Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195 ·
Heart Failure, Heart Diseases, Cardiovascular Diseases
RecruitingThe purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
PhaseNA
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 69 more
SponsorAbbott Medical Devices
▾Tap for detailsClick for full details — eligibility, all locations, contacts Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
NCT04838678 ·
Hypertension, Obesity
RecruitingThe purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic nervous system activity and blood flow during common laboratory physiological stress protocols (e.g. hypoxia, exercise), and in response to infusion of drugs that cause vasodilation or vasoconstriction.
PhaseEARLY_Phase 1
TypeInterventional
Age18 Years – 55 Years
WhereDallas, Texas, United States
SponsorUniversity of Texas Southwestern Medical Center
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
NCT06822738 · Primary Open Angle Glaucoma
RecruitingGlaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab interno (inside the eye) and ab externo (outside the eye) approach. Adverse events and intraocular pressure will be assessed. XEN63 is an investigational device for the treatment of intraocular pressure (IOP) in patients with glaucoma when both medical and conventional surgical treatments have failed (for US approval) and when medical treatments have failed (for outside US \[OUS\] approval). Participants will be placed in one of two groups called study arms. One group will receive the XEN63 gel stent ab interno (inside the eye) and the other group will receive the XEN63 gel stent ab externo (outside the eye). Approximately 130 participants aged 45 years or older with glaucoma will be enrolled in this study at approximately 32 sites in the United States. Participants will receive XEN63 implanted using either the ab interno approach or the ab externo approach on Day 1 and will be followed for 12 months. Participants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.
PhasePhase 3
TypeInterventional
Age45 Years
WhereGlendale, Arizona, United States + 28 more
SponsorAbbVie
▾Tap for detailsClick for full details — eligibility, all locations, contacts Hydrus® Microstent New Enrollment Post-Approval Study
NCT04553523 · Primary Open Angle Glaucoma
RecruitingThe purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.
PhaseNA
TypeInterventional
Age45 Years
WhereIrvine, California, United States + 21 more
SponsorAlcon Research
▾Tap for detailsClick for full details — eligibility, all locations, contacts Pulmonary Hypertension Association Registry
RecruitingThe PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH are treated according to recommended guidelines, and to see if there are certain factors that can lead to better or worse outcomes. PHAR will include information about people with PAH and CTEPH in the U.S. who are seen at participating PHA-accredited PH Care Centers. PHAR contains data about patient care and outcomes. Specifically, data in the PHAR includes information on diagnosis; clinical status; socioeconomic status; diagnosis test results; body size; treatment information; interest in participating in clinical trials; family health and social history; and information about smoking, alcohol, or drug use. Participants are followed over time, and provide updates such as changes in therapy, how often participants need to go to the hospital, and survival. Such information may help healthcare providers provide better care.
Phase—
TypeObservational
Age0 Years
WherePhoenix, Arizona, United States + 51 more
SponsorPulmonary Hypertension Association, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Assessing the Efficacy of Targeted Home Visits in the Management of Chronic Conditions
RecruitingThe purpose of study is to evaluate whether home visit programs are an effective method for HTN and T2DM management as compared to standard of care clinic visits.
PhaseNA
TypeInterventional
Age18 Years – 60 Years
WhereDallas, Texas, United States
SponsorUniversity of Texas Southwestern Medical Center
▾Tap for detailsClick for full details — eligibility, all locations, contacts IMPACT: Improving Maternal Postpartum Access to Care Through Telemedicine
NCT06218355 · Postpartum Complication
RecruitingThe purpose of this study is to compare two complex, multi-component evidence-based postpartum interventions in underserved populations of lower socioeconomic status in an effort to reduce maternal morbidity and mortality.
PhaseNA
TypeInterventional
Age18 Years
WhereAtlanta, Georgia, United States + 1 more
SponsorUniversity of Texas Southwestern Medical Center
▾Tap for detailsClick for full details — eligibility, all locations, contacts Global Paradise System US Post Approval Study
NCT06297291 ·
Hypertension, Cardiovascular Diseases, Vascular Diseases
RecruitingThe objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effectiveness of treatment with the Paradise System for patients with high blood pressure.
Phase—
TypeObservational
Age18 Years
WhereLong Beach, California, United States + 45 more
SponsorReCor Medical, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
NCT07220876 · Open Angle Glaucoma (OAG)
RecruitingA Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial
PhaseNA
TypeInterventional
Age45 Years
WhereGlendale, Arizona, United States + 13 more
SponsorAvisi Technologies Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
NCT06402968 · Intracerebral Hemorrhage, Stroke,
Hypertension RecruitingThe aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen.
Phase—
TypeObservational
Age18 Years – 100 Years
WhereIrvine, California, United States + 20 more
SponsorZeenat Qureshi Stroke Institute
▾Tap for detailsClick for full details — eligibility, all locations, contacts